| Kedrion Biopharma Inc. |
70573009902 |
Ryplazim 68.8 mg vial /1 vial per box |
2022-01-19 |
2064.0000 |
The manifestations of cPLGD in patients are very variable resulting in widely varying treatment regimen. Real world data with 12 patients on Expanded Access showed that except for 1 patient all other patients are treated with the PI recommended dosage of 6.6 mg/kg BW. In contrast, the frequency of treatment is handled more flexible and most patients are on an extended regimen outside of the PI recommended frequency of 2,3 or 4 days. The majority of patients is on a 7 day treatment regimen. Based on the real world data of these 12 patients, the mean weekly treatment costs are $15,410.54. The treatment is a long-term replacement therapy that reduces or eliminates the number/size of the lesions in a patient. In the clinical trial 78% of external and 75% of internal lesions were resolved at the end of week 48. No recurrent or new lesions developed during the 48 weeks. |
None |
500 |
1 |
1 |
2021-10-20 |
1.0000 |
None |
Acquisition part of a package for the purchase of the company Prometic; price for product cannot be singled out. |
None |
None |